Influenza/influenza
Influenza is a viral infectious disease spread through droplets from coughs and sneezes or by touching contaminated surfaces. Symptoms include fever, runny nose, sore throat, muscle pain, headache, coughing, and fatigue; they typically begin two days after exposure and usually last less than a week.
M2sr Vaccine Technology How Flugen Is Introducing New Solutions and Strategies for Influenza and Covid 19 Protection/m2sr-vaccine-technology-how-flugen-is-introducing-new-solutions-and-strategies-for-influenza-and-covid-19-protection

Blog

6 pages

A Better Flu Vaccine 4/a-better-flu-vaccine-4
Center for Infectious Disease Research Policy – The Compelling Need for Game-Changing Influenza Vaccines: An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future/center-for-infectious-disease-research-policy-the-compelling-need-for-game-changing-influenza-vaccines-an-analysis-of-the-influenza-vaccine-enterprise-and-recommendations-for-the-future
Influenza/category/influenza
OCR Annual Report – Every Day Counts/ocr-annual-report-every-day-counts

Press

6 pages

1 page

4 pages

Board of Directors/board-of-directors
Erik Iverson is CEO of the Wisconsin Alumni Research Foundation and assumed leadership of its investment and nonprofit patent and licensing organization in July 2016. He has over 20 years of executive experience.
Clinical Advisory Board/advisory-board
Dr. Belshe is an emeritus professor of infectious diseases and immunology at Saint Louis University. His expertise includes clinical trial design and execution, and his laboratory studies antibody responses to viral vaccines.
Executive Team/executive-team
Mr. Radspinner is co-founder, President and Chief Executive Officer of FluGen Inc. With Mr. Radspinner as President & CEO FluGen has raised over $40 million in capital and completed multiple human clinical trials with M2SR.
Leadership/leadership

1 page

For Investors/for-investors
Influenza causes about 3 million to 5 million cases of severe illness and 290,000 to 650,000 deaths worldwide each year. The annual influenza vaccine market is worth over $2 billion and is growing, while vaccines often work less than half the time.

1 page

Contact/contact
For inquiries about FluGen, M2SR, or investment opportunities, please get in touch.

1 page

Homepage/
FluGen, Inc. is developing a vaccine for influenza and respiratory disease using its M2SR Vaccine Platform. Its clinically tested vaccine candidate targets consistent efficacy, annual virus drift, and shedding.

1 page

Fcoi/fcoi
Financial Conflict Of Interest (FCOI) Policy for Public Health Service (PHS) Funding